Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 3 years, the average EBITDA Per Share Growth Rate was 14.20% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 10.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 7 years, the highest 3-Year average EBITDA Per Share Growth Rate of Next Science was 14.20% per year. The lowest was 0.50% per year. And the median was 5.00% per year.
Next Science (ASX:NXS) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Next Science 3-Year EBITDA Growth Rate Related Terms
ASX:NXS vs GCAN, PTPI, GRPS: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Next Science's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Next Science 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Next Science's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Next Science's 3-Year EBITDA Growth Rate falls into.
Next Science 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 14.20% mean?
Next Science (ASX:NXS) has a 3-Year EBITDA Growth Rate of 14.20% as of Jun. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Next Science and its competitors. This is 184% above median its historical median of 5.00. Over the past decade, Next Science's 3-Year EBITDA Growth Rate has ranged from 0.50 to 14.20.
Is Next Science's 3-Year EBITDA Growth Rate too high?
Next Science's current 3-Year EBITDA Growth Rate of 14.20% is 184% above median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 0.50 to a high of 14.20. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.90. Next Science's value of 14.20% is 59.6% above this industry median. Overall, Next Science has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Next Science's 3-Year EBITDA Growth Rate compare to GCAN and PTPI?
Next Science's 3-Year EBITDA Growth Rate of 14.20% can be compared against companies in the Drug Manufacturers industry. The industry median 3-Year EBITDA Growth Rate is 8.90. Next Science's value of 14.20% is 59.6% above this benchmark. Historically, Next Science's own 3-Year EBITDA Growth Rate has ranged from 0.50 to 14.20 over the past decade. While the company's 10-year median is 5.00 vs. the industry median of 8.90, Next Science has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.90, based on 807 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Next Science's current 3-Year EBITDA Growth Rate of 14.20% is 59.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Next Science and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Next Science's current 3-Year EBITDA Growth Rate is 14.20%, which is 184% above median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Next Science stock overvalued right now?
Next Science (ASX:NXS) has a current 3-Year EBITDA Growth Rate of 14.20%. The stock's GF Value™ is A$37.70, compared to a current price of A$0.15 — trading 99.6% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 14.20%, which is 184% above median its 10-year median of 5.00 and 59.6% above the Drug Manufacturers industry median of 8.90. Next Science's overall GF Score™ is 25/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Next Science (ASX:NXS), the current 3-Year EBITDA Growth Rate is 14.20% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Next Science (ASX:NXS) Overvalued in 2026?
Based on GuruFocus' analysis, Next Science stock appears to be undervalued.
The current stock price of A$0.15 is trading 99.6% below its estimated GF Value™ of A$37.70.
Key valuation signals for ASX:NXS:
3-Year EBITDA Growth Rate: 14.20% (184% above median its 10-year median of 5.00)
GF Value™: A$37.70 vs. price of A$0.15 (99.6% below fair value)
Industry Position: 59.6% above the Drug Manufacturers median
No single metric tells the full story. See the ASX:NXS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Next Science Ltd is a medical technology company. It is engaged in the development and commercialization of its proprietary Xbio technology to reduce the impact of biofilm-based infections in human health. Xbio is a non-toxic technology with efficacy in eradicating both biofilm-based and free-floating bacteria. Its products include Bactisure, XEPERIENCE and BLASTX. The company derives revenue from North America, New Zealand, and Australia.
25GF Score
Get the complete analysis for ASX:NXS
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:NXS has been successfully added to your 
